Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of
medicines that directly reprogramme the central dogma of biology to prevent and treat …

Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its
prevalence is rapidly increasing due to extended lifespans. Among the increasing number of …

The increasing number of approved nucleic acid therapeutics demonstrates the potential to
treat diseases by targeting their genetic blueprints in vivo. Conventional treatments …

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …

Carbon dots (CDs), as a new type of carbon-based nanomaterial, have attracted broad
research interest for years, because of their diverse physicochemical properties and …

Background Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-
thalassemia contains autologous CD34+ hematopoietic stem cells and progenitor cells …

There is growing need for a safe, efficient, specific and non-pathogenic means for delivery of
gene therapy materials. Nanomaterials for nucleic acid delivery offer an unprecedented …

Adeno-associated virus (AAV) vector-mediated gene delivery was recently approved for the
treatment of inherited blindness and spinal muscular atrophy, and long-term therapeutic …

This is an open access book. This book offers the first overview of the 'wicked problems'
literature, often seen as complex, open-ended, and intractable, with both the nature of the …

Modern experimental technologies can assay large numbers of biological sequences, but
engineered protein libraries rarely exceed the sequence diversity of natural protein families …